This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

The Protective Effects Of Treatment With Hyperbaric Oxygen Prior To Bypass Heart Surgery

This study has been completed.
Sponsor:
Collaborator:
North of England Medical & Hyperbaric Services
Information provided by:
Hull and East Yorkshire Hospitals NHS Trust
ClinicalTrials.gov Identifier:
NCT00623142
First received: February 14, 2008
Last updated: February 22, 2008
Last verified: January 2008
February 14, 2008
February 22, 2008
January 2005
January 2007   (Final data collection date for primary outcome measure)
  • Myocardial Hsp72 protein [ Time Frame: Intra-operative (During CABG) ]
  • Myocardial eNOS protein [ Time Frame: Intra-Operative (During CABG) ]
  • Serum Troponin-T [ Time Frame: Peri-operative ]
  • Serum soluble ICAM-1 [ Time Frame: Peri-operative ]
  • Serum soluble PSGL-1 [ Time Frame: Peri-operative ]
  • Serum soluble P-Selectin [ Time Frame: Peri-operative ]
  • Serum soluble E-Selectin [ Time Frame: Peri-operative ]
Same as current
No Changes Posted
  • All cardiovascular haemodynamic parameters as measured by a pulmonary artery catheter [ Time Frame: Peri-operative ]
  • Duration of mechanical ventilation [ Time Frame: Post Operative ]
  • Duration of endotracheal intubation [ Time Frame: post operative ]
  • Length of stay in ICU [ Time Frame: Post-operative ]
  • Blood loss [ Time Frame: Post operative ]
  • Inotrope usage [ Time Frame: Post operative ]
  • Atrial Fibrillation [ Time Frame: Post operative ]
  • Low cardiac output status [ Time Frame: Post operative ]
  • Pulmonary complications [ Time Frame: Post operative ]
  • Renal Complications [ Time Frame: Post operative ]
  • Cerebrovascular complications [ Time Frame: Post operative ]
  • Gastrointestinal complications [ Time Frame: Post operative ]
  • Wound complications [ Time Frame: Post operative ]
  • Cost of ICU stay [ Time Frame: Post operative ]
Same as current
Not Provided
Not Provided
 
The Protective Effects Of Treatment With Hyperbaric Oxygen Prior To Bypass Heart Surgery
The Effects of Hyperbaric Oxygen Preconditioning On Cardiovascular Protection & Ischemic Reperfusion Injury
The purpose of this study was to determine if treating patients who have coronary heart disease with hyperbaric oxygen (HBO) prior to coronary artery bypass graft (CABG) surgery reduces injury to the heart and vascular system during and after surgery. Furthermore, this study also aims to identify some of the post CABG clinical effects of HBO treatment prior to CABG.
Not Provided
Interventional
Phase 1
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Care Provider)
Primary Purpose: Health Services Research
  • Myocardial Reperfusion Injury
  • Cytoprotection
Drug: Hyperbaric Oxygen
100% Oxygen at 2.4 ATA for 30 minutes followed by 5 minutes break followed by 100% Oxygen at 2.4 ATA for another 30 minutes. This intervention was given about 4 to 5 hours prior to CABG
Other Name: Hyperbaric Oxygen Preconditioning
  • No Intervention: A
    Patients in this arm were not treated with HBO prior to CABG
  • Experimental: B
    Patients in this arm were treated with HBO prior to CABG
    Intervention: Drug: Hyperbaric Oxygen

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
81
January 2008
January 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients undergoing elective first time CABG
  • Patients with at least 1 vessel coronary artery disease undergoing on- pump CABG

Exclusion Criteria:

  • Age ≤ 20 years or ≥ 85 years
  • Ejection fraction < 30%
  • Unstable angina
  • Recent myocardial infarction (< 1 month)
  • Any additional cardiac disease (e.g. arrythmia, aneurysm, valvular/septal disease, dissection or elevated pulmonary artery pressure)
  • Any end stage organ failure (e.g. renal and respiratory failure)
  • History of chronic obstructive pulmonary disease (COPD)
  • Pneumothorax
  • Pulmonary bullae
  • Convulsions
  • Current history of malignancy
  • Severe myopia or intraocular lens
  • Patients on K+(ATP) Channel Openers e.g. Nicorandil, Oral Hypoglycemics, Opioid Analgesics, Catecholamines.
Sexes Eligible for Study: All
20 Years to 85 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
 
NCT00623142
R0047
04/Q1104/26
Yes
Not Provided
Not Provided
Dr. Jeysen Zivan Yogaratnam, Hull & East Yorkshire NHS Trust
Hull and East Yorkshire Hospitals NHS Trust
North of England Medical & Hyperbaric Services
Principal Investigator: Jeysen Z Yogaratnam, MB.BCh, BAO, MRCS Hull & East Yorkshire NHS Trust (Castle Hill Hospital), United Kingdom
Hull and East Yorkshire Hospitals NHS Trust
January 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP